We evaluated a combined panfungal PCR-reverse line blot (RLB) hybridization assay based on internal transcribed spacer 1 (ITS1) and ITS2 region polymorphisms to identify 159 Candida, Cryptococcus neoformans, and Aspergillus isolates (22 species). Its utility to identify fungal pathogens directly from 27 clinical specimens was also determined. ITS sequence analysis was performed to resolve discrepant identifications or where no RLB result was obtained. Species-specific ITS2-and ITS1-based probes correctly identified 155 of 159 isolates (98%) and 149 (93.7%) isolates, respectively. All strains were unambiguously differentiated with the exception of cross-reactivity between the Candida norvegensis probe and Candida haemulonii DNA product. Species identification of the pathogen was made for all 21 specimens (sensitivity of 100%) where species-specific probes were included in the RLB; however, there was no ITS2 probe-based hybridization signal for two specimens. Results were concordant with the culture results for 18 (85.7%) specimens. The assay was able to provide species identification in the absence of a culture result (two specimens) and to detect mixed infection (one specimen). The results indicate that the RLB assay is capable of reliably detecting yeasts and Aspergillus spp. in clinical specimens and that the incorporation of both ITS1-and ITS2-targeted probes is required for optimal sensitivity. The test has potential utility in the early diagnosis of invasive fungal infection, since "fungal" DNA was detected in all 27 specimens. Prior to incorporation of probes to detect other fungal species, ITS sequencing may be performed to achieve species identification.
Invasive fungal infections (IFIs) are an important cause of morbidity and mortality in severely ill and immunocompromised patients. Recent epidemiological trends indicate a significant shift towards species of Candida and Aspergillus other than Candida albicans and Aspergillus fumigatus and a diverse range of less common fungal opportunists (27, 29, 35) . Given the reduced susceptibility of many of these pathogens to standard antifungal agents (30, 35, 36) , timely and accurate identification to the species level is essential in guiding clinical management. Conventional culture-based phenotypic identification methods, however, are slow and prone to misidentification, particularly with less common or unusual species (20, 34) . In addition, the databases of commercial yeast identification systems do not contain all potential pathogens (34) .
Molecular approaches using PCR-based methods have been developed to provide rapid and accurate detection of fungi. In particular, the internal transcribed spacer (ITS) regions, ITS1 and ITS2, of the fungal ribosomal DNA gene complex, have shown promise as targets for species identification in a variety of formats, including DNA sequencing and DNA probe hybridization (9, 13, 22) . Both length and sequence polymorphisms within the ITS region have permitted accurate identification of pathogenic yeasts and molds (5-7, 12, 14, 22, 25, 33) . We previously developed a simple method to detect and identify Candida, Cryptococcus, and Aspergillus species using a panfungal nested PCR followed by hybridization with speciesspecific oligonucleotide probes targeting the ITS2 region in a reverse line blot (RLB) assay (31) .
For optimal sensitivity and specificity, combined analysis of both ITS regions (ITS1 and ITS2) has been proposed (5, 22) . We have now designed and incorporated into the RLB assay an additional set of probes targeting the ITS1 region and two fungus-specific probes (targeting the 5.8S rRNA region). In the present study, first we tested the ability of the new RLB assay to identify 159 reference and clinical isolates representing 22 fungal species. We then evaluated the RLB assay on clinical specimens obtained from patients with proven systemic mycoses to determine its utility in the early diagnosis of IFI. When the species identification was ambiguous or differed from the result obtained by culture-based methods (isolates and clinical specimens) or when a culture result was not obtained (clinical specimens), DNA sequence analysis of the ITS region was performed to resolve the uncertainty.
MATERIALS AND METHODS

Fungal isolates and clinical specimens.
Reference fungal strains were obtained from the American Type Culture Collection (ATCC), the Centraalbureau voor Schimmelcultures (CBS), the Australian Medical Mycology Reference Lab- Twenty-seven clinical specimens from 24 patients with proven IFI were evaluated (Table 2 ). Specimens included fresh tissue (n ϭ 13), formalin-fixed paraffin-embedded (PE) tissue (n ϭ 7), anticoagulated whole blood (n ϭ 4), bronchoalveolar lavage (BAL; n ϭ 2) fluid, and cerebrospinal fluid (CSF; n ϭ 1) samples.
DNA extraction. For fungal isolates, DNA extraction was performed as previously described (31) . For clinical specimens, DNA extractions were performed using the MagNA Pure LC instrument (Roche Diagnostics, Mannheim, Germany) in a class II laminar flow cabinet as outlined below.
(i) Blood, BAL fluid, and CSF specimens. The MagNA Pure LC total nucleic acid isolation kit (Roche Diagnostics) was used for extraction of blood, BAL, and CSF specimens with some modifications. Blood samples (500 l) were lysed with erythrocyte lysis buffer and incubated with sorbitol buffer and lyticase as outlined previously (11) . BAL (600-l) and CSF (100-to 200-l) samples were centrifuged at 16,100 ϫ g for 10 min, and the pellet was resuspended in 200 l of sorbitol buffer (1 M sorbitol, 100 mM EDTA, and 0.1% 2-mercaptoethanol) (38) and 200 U lyticase (Sigma-Aldrich, Castle Hill, Australia). After incubation at 37°C for 60 min, the spheroplasts were precipitated by centrifugation at 5,400 ϫ g for 5 min. The supernatant was discarded, and the pellet was resuspended in 200 l of distilled H 2 O before being transferred to the MagNA Pure sample cartridge for processing on the MagNA Pure LC instrument (Roche Diagnostics).
(ii) Fresh and PE tissue specimens. The MagNA Pure LC DNA isolation kit II (tissue) (Roche Diagnostics) was used to extract DNA from fresh and PE tissue specimens as previously described (21) .
Oligonucleotide design. Relevant fungal DNA sequences spanning the fungal ribosomal DNA gene complex (18S, 5.8S, and 28S) and the intervening ITS1 and ITS2 regions were accessed from GenBank and compared using the Pileup and Pretty programs provided by BioManager, ANGIS (http://biomanager.angis.org .au/). Three pairs of panfungal primers amplifying the ITS1 (its1Sb and its2Ab), ITS2 (its3Sb and its4Ab), and ITS1, 5.8S, and ITS2 regions (SR6RL/LR1L) ( Table 3) were designed from the multiple-sequence alignment. All primers were 5Ј-end biotin labeled (Sigma-Aldrich). Two panfungal oligonucleotide probes (its12Ap and its23Sp) were designed to target the 5.8S rRNA region (Table 3) . Species-specific fungal probes targeted the ITS1 or ITS2 region. The ITS2 probes have been described previously (31) . The ITS1 probes were either modified from published probe sequences (28) or designed de novo (Table 3 ). All oligonucleotide probes were 5Ј-hexylamine labeled (Sigma-Aldrich).
Multiplex PCR and nested PCR. (i) Fungal isolates. Multiplex PCR using the primer pairs, its1Sb/its2Ab and its3Sb/its4Ab, was performed to amplify the ITS1 and ITS2 regions. PCRs were performed in 25-l reaction mixtures containing 0.5 U HotStar Taq polymerase and 1ϫ PCR buffer (catalogue no. 203203; QIAGEN, Doncaster, Victoria, Australia), 125 M of each dATP, dCTP, dGTP, and dTTP (Roche Diagnostics), 0.5 M of each forward and reverse primer, and 5 l of DNA template. Amplification was performed on a Mastercycler gradient thermocycler (Eppendorf AG, North Ryde, Australia). The thermal cycling conditions were 95°C for 15 min, followed by 35 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 60 s, with a final extension step at 72°C for 10 min.
(ii) Clinical specimens. A nested PCR assay was used as follows: the firstround PCR targeted the ITS1, 5.8S, and ITS2 regions using the primer pair SR6RL/LR1L, and the second-round PCR amplified the ITS1 or ITS2 region using primer pairs its1Sb/its2Ab and its3Sb/its4Ab, respectively. The first-round (18, 31) . Briefly, the amplified PCR product was hybridized with membrane-bound probes at 60°C for 1 h, the membrane was washed twice (10 min each time) at 60°C with prewarmed (to 60°C) 2ϫ SSPE (1ϫ SSPE is 0.18 M NaCl, 10 mM NaH 2 PO 4 , and 1 mM EDTA [pH 7.7])-0.5% sodium dodecyl sulfate (SDS) and incubated in 15 ml of streptavidin-peroxidase conjugate (Roche Diagnostics) diluted 1:4,000 in 2ϫ SSPE-0.5% SDS for 60 min at 42°C. The membrane was further washed with 2ϫ SSPE-0.5% SDS at 42°C and then at 25°C. If present, bound PCR products were detected by chemiluminescence using ECL detection liquid (Amersham) and visualized by exposure for 7 min to an X-ray film (Hyperfilm; Amersham).
ITS sequencing. ITS sequence analysis was performed for fungal strains and clinical specimens which yielded either a discrepant (compared to culture) or ambiguous species identification result or when no hybridization signal was obtained by the RLB assay. For fungal strains, the ITS1, 5.8S, and ITS2 regions were amplified using the SR6RL and LR1L primer pair as described for multiplex PCR (see above). For clinical specimens, parameters used for PCR were identical to those used for the RLB assay except that in the second amplification, either the primer pair its1Sb/its2Ab or its3Sb/its4Ab was used. Both the ITS1 and ITS2 regions were amplified and analyzed. PCR products were purified using the PCR Product Pre-sequencing kit (USB Corporation, Cleveland, OH) and were sequenced using forward primer and the BigDye Terminator (version 3.1) cycle sequencing kit in the ABI PRISM 3100 genetic analyzer (Applied Biosystems).
Sequences were entered into a BLASTn sequence analysis search (2) (accessed via http://biomanager.angis.org.au/).
RESULTS
Fungal isolates.
The universal fungal primers SR6RL and LR1L amplified the ITS1, 5.8S, and ITS2 regions for all 159 isolates. Species-specific ITS2 probes correctly identified 155 (98%) isolates by the RLB assay; the corresponding ITS1 probes identified 149 of 159 (93.7%) strains (Table 1) . With one exception (see below), the ITS1-and ITS2-specific RLB assays clearly identified major Candida species, including C. zeylanoides and C. guilliermondii (Table 1 ). The assays did not differentiate between members of the C. neoformans complex.
RLB assay results, using both ITS1 and ITS2 species-specific probes, correlated with culture identification for 149 of 159 (93.7%) strains. Isolates that produced inconsistent results or no hybridization signal are listed in Table 4 . Four C. haemulonii strains hybridized with both (ITS1 and ITS2) C. haemulonii-specific and C. norvegensis-specific probes; in all instances, ITS sequence analysis yielded sequences with 100% identity to C. haemulonii sequences in the GenBank database. In the ITS regions employed for probe design, C. haemulonii-and C. norvegensis-specific sequences had sequence identities of 35% and 55% for the ITS1 and ITS2 region, respectively. The other discrepant results involved six of the nine A. niger strains (AS7, AS31, AS33, AS36, AS37, and AS39) studied. These isolates hybridized with the ITS2, but not the ITS1, A. niger-specific probe (Table 4 ). Sequence analysis of the ITS1 region for all six strains demonstrated 100% identity to A. niger ATCC 16888 sequence (GenBank accession no. AY373852); this sequence showed a single base polymorphism (from A to G) with the GenBank sequence used to design the ITS1-based probe (GenBank accession no. AY213633). Clinical specimens. The RLB assay detected fungal DNA in all 27 specimens using the panfungal probe. The identification of the fungal pathogen, as determined by phenotypic-based methods, RLB, and/or ITS sequence analysis are summarized in Table 2 . RLB analysis assigned a species identification for all 21 specimens for which species-specific probes were available. The sensitivities of the assay with the ITS1-and ITS2-based probes were 100% (21 of 21) and 90.5% (19 of 21), respectively. Hybridization occurred with both probes for all but two specimens (patients 3 and 12) where a hybridization signal was observed only with the ITS1 probe.
Concordant results with culture were obtained for 18 of 21 (85.7%) specimens using both ITS1 and ITS2 species-specific probes. For two specimens (from patient 18), RLB provided a species identification in the absence of a culture result. For the remaining specimen (nasal mucosa; patient 19), A. fumigatus was recovered on culture but both A. fumigatus and A. flavus DNA were detected by RLB (Table 2 ). ITS sequence analysis detected A. fumigatus DNA only (100% sequence identity to A. fumigatus sequences in GenBank accession no. AY939790). Examination of A. fumigatus-and A. flavus-specific ITS sequences in the region targeted by the probes revealed they were dissimilar.
No hybridization signal was observed for six specimens (patients 21 to 24; Table 2 ). In these instances, ITS1 and ITS2 sequencing identified the pathogen to be a fungus not represented by probes on the RLB (as described previously for specimens from patients 23 and 24 [21] and in this study for specimens from patients 21 and 22). The molecular identification was consistent with culture and/or histological diagnosis for five of six (83.3%) specimens. The single discrepancy involved a skin biopsy specimen (patient 21) where culture-based methods identified the pathogen as Exophiala jeanselmei but sequencing revealed results with 99% identity to Exophiala 
DISCUSSION
This study demonstrates the feasibility of combining a panfungal nested PCR with probe hybridization technology in a RLB format to identify clinically important fungal pathogens. Important features of this RLB assay, which incorporates both ITS1-and ITS2-targeted probes, include the high sensitivity (98%) for the identification of 22 fungal species and the ability to identify fungal pathogens directly from clinical specimens.
The validity of the RLB assay was confirmed by analysis of a large number of the more common pathogenic yeasts and Aspergillus species. With one exception, major Candida spp. were unambiguously differentiated. The cross-reactivity between the C. norvegensis probe and C. haemulonii DNA product is unexplained, as multiple GenBank database ITS sequences in the region employed for probe design between these species are dissimilar. In contrast to previous observations, C. guilliermondi was differentiated from C. zeylanoides (28, 31) . Both C. neoformans probes (CNEO [31] and CRY [ Table 3 ]) were designed on conserved sequences and thus hybridized with all members of C. neoformans complex. Likewise, previous ITS-based analyses have not provided species identification within C. neoformans (7, 15, 22) ; however, a more recent study found diversity in the ITS region to be useful in differentiating between species and varieties of C. neoformans (17) . If required, the RLB used in our study can be modified to incorporate probes specific for these species/varieties.
Incorporation of both ITS1 and ITS2 probes into the assay enabled major Aspergillus spp. to be identified. The ability of the current assay to distinguish between members of the A. fumigatus clade (e.g., Neosartorya fischeri, Aspergillus lentus) was not tested. This distinction is clinically relevant, as A. lentulus and Neosartorya spp. have been reported to be less susceptible in vitro to antifungal agents (3) . Previous analyses reveal little difference between the ITS sequences of these closely related species (3, 21) , suggesting that probes based on alternative gene targets (e.g., the ␤-tubulin and rodlet A genes) would be required (3) .
The results from this study support the notion that the use of both ITS loci for fungal identification provides more informative data than that of either locus alone (5, 7). For fungal isolates, ITS2 sequence polymorphisms were more species specific than their ITS1 counterpart; for example, in A. niger, intraspecies ITS1 sequence divergence was higher than in the ITS2 region (Table 4) . This has implications for study of potential subtypes of A. niger and other Aspergillus spp. Conversely, DNA amplified from two clinical specimens hybridized with only the ITS1 probe (patients 3 and 12, Table 2 ). When these same specimens were subjected to ITS sequence analysis, only the ITS1 (and not ITS2) region was amplified. Similarly, for specimens from patients 21 and 22, DNA sequence analysis was successful for the ITS1, but not the ITS2, region. The reasons for these results are not readily explained. Failure of the ITS2 probe to hybridize to the DNA is unlikely to be due to degradation of fungal DNA, as the ITS1 region was successfully amplified and analyzed. Others have reported yeast identification rates of 96.8% and 99.7% based on ITS1 and ITS2 sequencing, respectively, of fungal cultures (22) . The relative utility of ITS1 and ITS2 loci in determining species identification and phylogenetic relationships is the subject of ongoing study.
We successfully applied the RLB assay to identify Candida, Aspergillus, and Cryptococcus spp. in clinical specimens, including blood and PE tissue samples, with high (100% for ITS1-based probes and 90.5% for ITS2-based probes) sensitivity. In particular, the assay was able to provide a diagnosis in the absence of a culture result (patient 18) and was capable of diagnosing possible mixed infection (patient 19). Furthermore, the results indicate that the RLB has potential utility in the early diagnosis of IFI, as it detected the presence of a "fungal pathogen" in all cases of IFI caused by species not represented by probes on the RLB. In one instance (patient 21, Table 2 ), the pathogen was finally determined to be E. spinifera by ITS sequence analysis but identified morphologically as E. jeanselmei. Comparison of GenBank ITS sequences of both these species revealed the two can be easily distinguished (20) . Identification of Exophiala spp. is problematic due to variable morphological characteristics within this genus (14, 32) . It is likely the culture-based identification was incorrect.
While probe hybridization technology has been successfully used for identification of fungal isolates (1, 2, 8, 23, 24) , species identification from clinical specimens has remained a challenge. Real-time PCR systems have been developed to meet these demands but are limited by false-negative and falsepositive results inherent in PCR and the number of fungal species that can be simultaneously identified (4, 16, 26) . We chose a simple nested PCR-RLB format as an alternative to culture for fungal identification given the advantages of low cost, inherent high sensitivity, good specificity (10; this study), and the capacity to simultaneously analyze multiple strains against multiple probes (10) . Although only 22 probes (two probes per species) were used in this study, up to 43 may be incorporated (one probe per species), extending the range of pathogens that can be identified. This flexibility and versatility also allow laboratories to readily modify or "customize" the RLB format to meet specific requirements or for use in a particular clinical setting. For example, in the rapid diagnosis of fungemia, species-specific probes representative of causative agents of fungemia other than Candida spp., e.g., Scedosporium prolificans, may be included.
The identification of uncommon but emerging fungal pathogens continues to pose a challenge. Based on the results of this study, for suspected Candida, Cryptococcus, or Aspergillus isolates, the RLB assay is a reliable alternative to conventional identification methods, especially if there is a need to identify more than one isolate at the same time. Notably, the assay performed well when applied to clinical specimens. We envisage it will be most useful if culture-based identification is not made or when clinical specimens fail to be submitted for culture, as can occur following surgery. In the event a "fungus" is detected on RLB but not identified further due to lack of inclusion of the species-specific probe in the assay, the more expensive and time-consuming ITS sequencing can be performed. ITS sequence analysis to identify fungal pathogens directly from tissue specimens has been successfully implemented in our laboratory, but the turnaround time is significantly increased relative to RLB by our outsourcing of the DNA sequencing (21) . Evaluation of larger numbers of specimens is required to position the RLB assay and/or DNA sequence analysis within routine diagnostic algorithms.
